KR20240027896A - 이중 모드 방사성 트레이서 및 치료법 - Google Patents

이중 모드 방사성 트레이서 및 치료법 Download PDF

Info

Publication number
KR20240027896A
KR20240027896A KR1020247006169A KR20247006169A KR20240027896A KR 20240027896 A KR20240027896 A KR 20240027896A KR 1020247006169 A KR1020247006169 A KR 1020247006169A KR 20247006169 A KR20247006169 A KR 20247006169A KR 20240027896 A KR20240027896 A KR 20240027896A
Authority
KR
South Korea
Prior art keywords
oligo
acid
amide
bond
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247006169A
Other languages
English (en)
Korean (ko)
Inventor
알렉산더 요세프 우르제르
한스-위르겐 웨스테르
마티아스 요하네스 에이베르
Original Assignee
테크니쉐 우니베르지테트 뮌헨
테크니쉐 우니베르지테트 뮌헨 - 클리니쿰 레흐츠 데르 이사르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테크니쉐 우니베르지테트 뮌헨, 테크니쉐 우니베르지테트 뮌헨 - 클리니쿰 레흐츠 데르 이사르 filed Critical 테크니쉐 우니베르지테트 뮌헨
Publication of KR20240027896A publication Critical patent/KR20240027896A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine (AREA)
KR1020247006169A 2017-07-28 2018-07-30 이중 모드 방사성 트레이서 및 치료법 Pending KR20240027896A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17183795.8 2017-07-28
EP17183795 2017-07-28
PCT/EP2018/070533 WO2019020831A1 (en) 2017-07-28 2018-07-30 AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES
KR1020207005589A KR102752620B1 (ko) 2017-07-28 2018-07-30 이중 모드 방사성 트레이서 및 치료법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207005589A Division KR102752620B1 (ko) 2017-07-28 2018-07-30 이중 모드 방사성 트레이서 및 치료법

Publications (1)

Publication Number Publication Date
KR20240027896A true KR20240027896A (ko) 2024-03-04

Family

ID=59501286

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247006169A Pending KR20240027896A (ko) 2017-07-28 2018-07-30 이중 모드 방사성 트레이서 및 치료법
KR1020207005589A Active KR102752620B1 (ko) 2017-07-28 2018-07-30 이중 모드 방사성 트레이서 및 치료법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207005589A Active KR102752620B1 (ko) 2017-07-28 2018-07-30 이중 모드 방사성 트레이서 및 치료법

Country Status (20)

Country Link
US (4) US11413360B2 (cg-RX-API-DMAC7.html)
EP (3) EP4424378A3 (cg-RX-API-DMAC7.html)
JP (2) JP7059372B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240027896A (cg-RX-API-DMAC7.html)
CN (1) CN111132700B (cg-RX-API-DMAC7.html)
AU (2) AU2018308699B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020001785A2 (cg-RX-API-DMAC7.html)
CA (1) CA3071315A1 (cg-RX-API-DMAC7.html)
DK (1) DK3658194T3 (cg-RX-API-DMAC7.html)
EA (1) EA202090370A1 (cg-RX-API-DMAC7.html)
ES (1) ES3011272T3 (cg-RX-API-DMAC7.html)
FI (1) FI3658194T3 (cg-RX-API-DMAC7.html)
HU (1) HUE070098T2 (cg-RX-API-DMAC7.html)
IL (2) IL272291B2 (cg-RX-API-DMAC7.html)
MX (2) MX2020000352A (cg-RX-API-DMAC7.html)
PL (1) PL3658194T3 (cg-RX-API-DMAC7.html)
PT (1) PT3658194T (cg-RX-API-DMAC7.html)
SG (1) SG11202000725WA (cg-RX-API-DMAC7.html)
WO (1) WO2019020831A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202000467B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240027896A (ko) 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법
BR112021012110A2 (pt) * 2019-01-30 2021-09-08 Technische Universität München Radiofarmacêuticos substituídos por aceptor de fluoreto de silício
WO2020157177A1 (en) * 2019-01-30 2020-08-06 Technische Universität München Psma binding dual mode radiotracer and therapeutic
CA3128406A1 (en) * 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
CN112168978B (zh) * 2019-07-03 2022-01-11 北京大学 一种抗体偶联药物及其药物组合物与应用
EP4041213A4 (en) * 2019-10-29 2023-12-27 The Cleveland Clinic Foundation Psma-targeting imaging agents
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
GB202005282D0 (en) * 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
EP4185336A1 (en) 2020-07-23 2023-05-31 Technische Universität München Silicon-containing ligand compounds
KR20230066382A (ko) 2020-09-03 2023-05-15 큐리엄 유에스 엘엘씨 64Cu-DOTATATE의 스케일 업을 위한 방사성표지 및 제형
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
IL305134A (en) * 2021-02-15 2023-10-01 Technische Universit?T M?Nchen Dual mode radio and medical tracker
CA3215723A1 (en) * 2021-04-02 2022-10-06 Advanced Accelerator Applications Diagnostic methods of prostate cancer
JP2024517971A (ja) * 2021-05-14 2024-04-23 テクニシェ ユニバーシタット ミュンヘン 放射性医薬品のソマトスタチン受容体リガンドおよびその前駆体
GB202108779D0 (en) 2021-06-18 2021-08-04 Blue Earth Diagnostics Ltd Si-at therapeutic/diagnostic compounds
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
US20250313579A1 (en) * 2021-08-05 2025-10-09 Technische Universität München Ligand compounds comprising a chelating group as a bridging group
GB202113646D0 (en) 2021-09-24 2021-11-10 Blue Earth Diagnostics Ltd Method of preparation of 18F labelled silyl-fluoride compounds
CN114671806B (zh) * 2022-04-08 2024-03-01 上海如絮生物科技有限公司 一种亲水性吡啶衍生物、中间体、其制备方法及应用
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds
JP2025525111A (ja) 2022-07-29 2025-08-01 テクニシェ ユニバーシタット ミュンヘン 放射性医薬品のためのケイ素系フッ化物アクセプター基
WO2024054226A1 (en) * 2022-09-06 2024-03-14 Hoang Ba Xuan Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment
CA3264385A1 (en) * 2022-09-20 2024-03-28 Universität Augsburg NEW MINIGASTRINE-DERIVED CHOLECYSTOKIN 2 RECEPTOR-BINDING MOLECULES FOR TARGETED IMAGING AND RADIOTHERAPY
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白(fap)抑制劑、fap結合物及其診斷與治療用途
IL319722A (en) 2022-09-23 2025-05-01 Nuclidium Ag High purity radionuclides and their diagnostic and medical uses
CN120417945A (zh) * 2022-11-14 2025-08-01 阿克提斯肿瘤学公司 肾脏中小蛋白滞留的减少
KR20260085122A (ko) 2023-09-29 2026-06-08 악티스 온콜로지, 인크. 미니단백질, 접합체 및 이의 용도
GB202316239D0 (en) 2023-10-24 2023-12-06 Blue Earth Diagnostics Ltd Therapeutic combination
WO2025250644A1 (en) * 2024-05-28 2025-12-04 Case Western Reserve University Fluorescent nuclide-containing agents for detecting and treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7384394A (en) * 1993-06-30 1995-01-24 Akzo Nobel N.V. Chelating compounds
EP1420831A1 (en) * 2001-07-27 2004-05-26 Targesome, Inc. Lipid constructs as therapeutic and imaging agents
CN102626522B (zh) * 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
CA2949936C (en) * 2014-06-10 2022-10-18 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
EP3209336B1 (en) 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20160287730A1 (en) * 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
EP3303349B1 (en) * 2015-05-26 2022-07-06 The Regents of the University of California Novel heteroaromatic silicon-fluoride-acceptors useful for 18f labeling of molecules and biomolecules, and methods of preparing same
KR20240027896A (ko) 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법
DK3723815T3 (da) * 2017-12-11 2022-07-11 Univ Muenchen Tech PSMA ligander til billeddannelse og endoradioterapi
CA3128406A1 (en) 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
WO2020157177A1 (en) 2019-01-30 2020-08-06 Technische Universität München Psma binding dual mode radiotracer and therapeutic

Also Published As

Publication number Publication date
MX2020000352A (es) 2020-08-17
US20260021211A1 (en) 2026-01-22
EA202090370A1 (ru) 2020-05-25
KR20200064057A (ko) 2020-06-05
EP4424378A3 (en) 2024-12-11
US12453787B2 (en) 2025-10-28
ES3011272T3 (en) 2025-04-07
FI3658194T3 (fi) 2025-02-28
JP2020528461A (ja) 2020-09-24
IL272291B1 (en) 2025-02-01
WO2019020831A1 (en) 2019-01-31
AU2018308699A1 (en) 2020-01-23
AU2024200440A1 (en) 2024-02-08
SG11202000725WA (en) 2020-02-27
US20220370649A1 (en) 2022-11-24
JP2022101601A (ja) 2022-07-06
EP3658194B1 (en) 2024-11-27
PT3658194T (pt) 2025-02-13
US12390540B2 (en) 2025-08-19
IL272291B2 (en) 2025-06-01
EP3658194A1 (en) 2020-06-03
CA3071315A1 (en) 2019-01-31
KR102752620B1 (ko) 2025-01-10
NZ760537A (en) 2026-01-30
IL318092A (en) 2025-02-01
AU2024200440B2 (en) 2025-04-24
PL3658194T3 (pl) 2025-09-15
MX2023007914A (es) 2023-07-13
CN111132700B (zh) 2022-12-13
US20200197545A1 (en) 2020-06-25
DK3658194T3 (da) 2025-02-17
US20250121102A1 (en) 2025-04-17
EP4424378A2 (en) 2024-09-04
HUE070098T2 (hu) 2025-05-28
EP4000640A1 (en) 2022-05-25
ZA202000467B (en) 2022-06-29
AU2018308699B2 (en) 2023-11-30
CN111132700A (zh) 2020-05-08
US11413360B2 (en) 2022-08-16
BR112020001785A2 (pt) 2020-09-29
IL272291A (en) 2020-03-31
JP7059372B2 (ja) 2022-04-25

Similar Documents

Publication Publication Date Title
US12453787B2 (en) Dual mode radiotracer and-therapeutics
KR102951950B1 (ko) 암 진단 영상화제들
CN113677400B (zh) 结合psma的双模式放射性示踪剂及治疗剂
EP4023250A1 (en) Dual mode radiotracer and -therapeutics
KR20230160806A (ko) 이중 모드 방사성 트레이서 및 치료법
US20230277698A1 (en) Silicon-containing ligand compounds
US20250313579A1 (en) Ligand compounds comprising a chelating group as a bridging group
HK40022705A (en) Dual mode radiotracer and -therapeutics
HK40022705B (en) Dual mode radiotracer and -therapeutics
EP3494998A1 (en) Glycosylated psma inhibitors for imaging and endoradiotherapy
EA046402B1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство
EA052134B1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство
HK40055543A (en) Cancer diagnostic imaging agents
HK40055543B (en) Cancer diagnostic imaging agents

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701